Actinium Pharmaceuticals, Inc.
(NYSE Amex Equities : ATNM)

( )
ATNM After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. 1.60%78.211.0%$1948.71m
AMGNAmgen, Inc. -1.66%205.411.3%$885.20m
REGNRegeneron Pharmaceuticals, Inc. -1.09%493.322.6%$821.01m
BIIBBiogen, Inc. -1.30%300.511.5%$730.72m
MRNAModerna, Inc. 4.94%34.840.0%$587.89m
VRTXVertex Pharmaceuticals, Inc. -1.59%238.311.9%$585.26m
ILMNIllumina, Inc. -3.48%263.503.5%$455.53m
ALXNAlexion Pharmaceuticals, Inc. -0.64%89.772.0%$278.42m
AAgilent Technologies, Inc. -2.63%70.391.6%$217.41m
INCYIncyte Corp. 1.97%78.592.5%$187.57m
EXASEXACT Sciences Corp. -3.21%55.7521.0%$173.77m
BMRNBioMarin Pharmaceutical, Inc. -2.15%84.214.3%$161.37m
SGENSeattle Genetics, Inc. -1.82%116.516.1%$157.34m
NVAXNovavax, Inc. 12.63%15.61114.7%$131.54m
SRPTSarepta Therapeutics, Inc. -2.46%93.6214.0%$100.23m

Company Profile

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.